Jones Nicole S sold $5.4M of CI

Jones Nicole S (See Remarks) sold 19,436 shares of Cigna Group (CI) at $276.27 ($5.37M total) on 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jones Nicole S
Published Aug 6, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CI
Neutral
high confidence
Mentioned
$CI
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CINeutralLow
01

Why it matters

The newest concrete fact is the sale size ($5.37M) and execution details (19,436 shares at $276.27) with a pre-arranged plan, which generally reduces informational content about near-term business outlook.

02

Market read

Traders may note the filing for sentiment monitoring, but it is unlikely to drive a fundamental repricing without accompanying company-specific news.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, no reason for sale, and no follow-on purchases, limiting interpretability.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-06 for a sale executed 2026-08-04.

Background

The article is an SEC Form 4 insider transaction disclosure for Cigna Group, reporting an officer’s open-market sale executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$CINeutralHigh confidence
Context

Cigna Group Form 4 shows officer Jones Nicole S sold 19,436 shares at $276.27 on 2026-08-04 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move based solely on this filing.

Evidence & confidence

The filing is a routine insider transaction with an explicit 10b5-1 pre-arranged plan; it does not disclose new company performance, guidance, or regulatory developments.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or earnings changes.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, large dollar-value insider selling can still coincide with private views on risk or liquidity needs, so some traders may briefly fade the stock.

Key entities

  • Cigna Group

    CI, the company whose Form 4 insider sale is disclosed.

  • Jones Nicole S

    Officer who sold 19,436 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

UnitedHealth and other insurance stocks drag down the Dow after CMS proposes new anti-fraud rule

UnitedHealth (UNH), Humana (HUM), Cigna (CI), and CVS Health (CVS) stocks fell 8%, 8%, 2%, and 3% respectively, dragging down the Dow after CMS proposed a new anti-fraud rule. The rule, called CRUSH, aims to increase audits and recover improper payments, potentially saving $90B over 10 years. Oppenheimer analysts expect legal challenges and note savings may not be broad.

$UNHHighAI 8/10

Positive Medicaid signals, open enrollment trends: Recapping major payers' Q3 results

UnitedHealth Group reported Q3 profit of $4.1B (up from $2.3B YoY) and revenue of $112.7B. CVS Health earned $2.2B (up from a $4B loss YoY) on $108.4B revenue, announcing a split of its pharmacy business. Cigna and Elevance Health each posted $1.4B profit. Centene reduced losses to $71M (from $6.6B YoY) on $50.6B revenue. Humana saw $162M profit (down from $195M) on $41.15B revenue, with positive Medicare enrollment trends.